ANIP ANI Pharmaceuticals Inc.

ANI Pharmaceuticals Inc.

Biotechnology: Pharmaceutical Preparations

Health Care

ANI Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract manufacturing for other pharmaceutical companies. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. The company was founded in 2001 and is headquartered in Baudette, Minnesota.

IPO Year:

Exchange: NASDAQ

Website: anipharmaceuticals.com

Peers

$ELOX

Recent Analyst Ratings for ANI Pharmaceuticals Inc.

Date	Price Target	Rating	Analyst
3/14/2025	$80.00	Buy	Jefferies
3/12/2025	$85.00	Overweight	Analyst
12/11/2024	$80.00	Outperform	Leerink Partners
10/11/2024	$68.00	Overweight	Piper Sandler
3/15/2024	$80.00	Overweight	CapitalOne
8/22/2023	$60.00 → $73.00	Buy	H.C. Wainwright
3/1/2023	$55.00	Buy	Guggenheim
9/7/2022	$50.00	Buy	H.C. Wainwright
11/2/2021	$60.00 → $65.00	Outperform	Raymond James
11/2/2021	$70.00	Buy	Truist

See more ratings

ANI Pharmaceuticals Inc.

Peers

Recent Analyst Ratings for ANI Pharmaceuticals Inc.

ANI Pharmaceuticals Inc. SEC Filings

ANI Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

ANI Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

ANI Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

SEC Form 10-Q filed by ANI Pharmaceuticals Inc.

ANI Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

SEC Form DEFA14A filed by ANI Pharmaceuticals Inc.

ANI Pharmaceuticals Inc. filed SEC Form 8-K: Other Events

SEC Form DEFA14A filed by ANI Pharmaceuticals Inc.

SEC Form DEF 14A filed by ANI Pharmaceuticals Inc.

SEC Form PRE 14A filed by ANI Pharmaceuticals Inc.

ANI Pharmaceuticals Inc. Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Jefferies initiated coverage on ANI Pharma with a new price target

Analyst initiated coverage on ANI Pharma with a new price target

Leerink Partners initiated coverage on ANI Pharma with a new price target

Piper Sandler initiated coverage on ANI Pharma with a new price target

CapitalOne initiated coverage on ANI Pharma with a new price target

H.C. Wainwright reiterated coverage on ANI Pharma with a new price target

Guggenheim initiated coverage on ANI Pharma with a new price target

H.C. Wainwright initiated coverage on ANI Pharma with a new price target

Raymond James reiterated coverage on ANI Pharmaceuticals with a new price target

Truist initiated coverage on ANI Pharma with a new price target

ANI Pharmaceuticals Inc. FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

FDA Approval for HYDROCODONE BITARTRATE AND IBUPROFEN

FDA Approval for OXYCODONE AND ASPIRIN

FDA Approval for EZETIMIBE AND SIMVASTATIN

FDA Approval for TEMOZOLOMIDE

ANI Pharmaceuticals Inc. Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SR. VP, GENERAL COUNSEL & SEC. Cook Meredith sold $24,548 worth of shares (400 units at $61.37), decreasing direct ownership by 0.50% to 79,345 units (SEC Form 4)

Director Haughey Thomas was granted 4,336 shares, increasing direct ownership by 8% to 55,862 units (SEC Form 4)

Director Leonard Matthew J was granted 4,336 shares, increasing direct ownership by 36% to 16,329 units (SEC Form 4)

Director Pera Antonio R was granted 4,336 shares, increasing direct ownership by 14% to 35,373 units (SEC Form 4)

Director Tannenbaum Renee P was granted 4,336 shares, increasing direct ownership by 19% to 26,957 units (SEC Form 4)

Director Thoma Jeanne was granted 4,336 shares, increasing direct ownership by 11% to 44,945 units (SEC Form 4)

Director Walsh Patrick D was granted 4,336 shares, increasing direct ownership by 6% to 79,048 units (SEC Form 4)

SVP, GENERICS Gutwerg Ori sold $52,922 worth of shares (881 units at $60.07), decreasing direct ownership by 0.97% to 89,897 units (SEC Form 4)

HEAD OF RARE DISEASE Mutz Christopher sold $241,800 worth of shares (4,000 units at $60.45), decreasing direct ownership by 4% to 107,317 units (SEC Form 4)

SR. VP, GENERAL COUNSEL & SEC. Cook Meredith sold $24,880 worth of shares (400 units at $62.20), decreasing direct ownership by 0.50% to 79,745 units (SEC Form 4)